Annotated Medicine and Device Lists


Rifampicin

This medicine is present in:

List Section Observation
Cuba 6.2.10 Antituberculosos y antileprosos No observations

This medicine is present in:

List Section Observation
WHO Model List of Essential Medicines (2021) 6.2.5. Antituberculosis medicines This medicine is only for children.
PAHO Strategic Fund Medicine List 2.3. Antituberculosis med. No observations

This medicine is present in:

List Section Observation
Colombia 01. Leprostatics No observations
Peru 6.2.4 Anti-Tuberculosis No observations

This medicine is present in:

List Section Observation
WHO Model List of Essential Medicines (2021) 6.2.4. Antileprosy medicines No observations
WHO Model List of Essential Medicines (2021) 6.2.5. Antituberculosis medicines No observations
PAHO Strategic Fund Medicine List 2.3. Antituberculosis med. Others observations:
Medicines used in the treatment of leprosy should never be used except in combination.
Peru 6.2.3 Anti-Leprosy No observations
Chile Essential and Prioritized Medications No observations

This medicine is present in:

List Section Observation
WHO Model List of Essential Medicines (2021) 6.2.4. Antileprosy medicines No observations
WHO Model List of Essential Medicines (2021) 6.2.5. Antituberculosis medicines No observations
PAHO Strategic Fund Medicine List 2.3. Antituberculosis med. Others observations:
Medicines used in the treatment of leprosy should never be used except in combination.
Colombia 01. Leprostatics No observations
Bolivia LINAME 2011 - 2013 No observations
Peru 6.2.3 Anti-Leprosy No observations
Peru 6.2.4 Anti-Tuberculosis No observations
Ecuador Essential Medicines List - Ecuador No observations
Chile Essential and Prioritized Medications No observations

This medicine is present in:

List Section Observation
Bolivia LINAME 2011 - 2013 No observations
Ecuador Essential Medicines List - Ecuador No observations
Chile Essential and Prioritized Medications No observations

Information Resources: Rifampicin

Loading ...
Loading ...
Loading ...
No information available